| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Protein Design Labs, Fremont, CA 94555
The serum half-life of IgG Abs is regulated by the neonatal Fc receptor (FcRn). By binding to FcRn in endosomes, IgG Abs are salvaged from lysosomal degradation and recycled to the circulation. Several studies have demonstrated a correlation between the binding affinity of IgG Abs to FcRn and their serum half-lives in mice, including engineered Ab fragments with longer serum half-lives. Our recent study extended this correlation to human IgG2 Ab variants in primates. In the current study, several human IgG1 mutants with increased binding affinity to human FcRn at pH 6.0 were generated that retained pH-dependent release. A pharmacokinetics study in rhesus monkeys of one of the IgG1 variants indicated that its serum half-life was 
2.5-fold longer than the wild-type Ab. Ag binding was unaffected by the Fc mutations, while several effector functions appeared to be minimally altered. These properties suggest that engineered Abs with longer serum half-lives may prove to be effective therapeutics in humans.
This article has been cited by other articles:
|
|
 |
|
  Y. A. Yeung, M. K. Leabman, J. S. Marvin, J. Qiu, C. W. Adams, S. Lien, M. A. Starovasnik, and H. B. Lowman Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates J. Immunol., June 15, 2009; 182(12): 7663 - 7671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sack, A. Paetz, R. Kunert, M. Bomble, F. Hesse, G. Stiegler, R. Fischer, H. Katinger, E. Stoeger, and T. Rademacher Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures FASEB J, June 1, 2007; 21(8): 1655 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Mascelli, H. Zhou, R. Sweet, J. Getsy, H. M. Davis, M. Graham, and D. Abernethy Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development J. Clin. Pharmacol., May 1, 2007; 47(5): 553 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Datta-Mannan, D. R. Witcher, Y. Tang, J. Watkins, and V. J. Wroblewski Monoclonal Antibody Clearance: IMPACT OF MODULATING THE INTERACTION OF IgG WITH THE NEONATAL Fc RECEPTOR J. Biol. Chem., January 19, 2007; 282(3): 1709 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Datta-Mannan, D. R. Witcher, Y. Tang, J. Watkins, W. Jiang, and V. J. Wroblewski Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates Drug Metab. Dispos., January 1, 2007; 35(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Vaccaro, R. Bawdon, S. Wanjie, R. J. Ober, and E. S. Ward Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies PNAS, December 5, 2006; 103(49): 18709 - 18714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Petkova, S. Akilesh, T. J. Sproule, G. J. Christianson, H. Al Khabbaz, A. C. Brown, L. G. Presta, Y. G. Meng, and D. C. Roopenian Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease Int. Immunol., December 1, 2006; 18(12): 1759 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F. Dall'Acqua, P. A. Kiener, and H. Wu Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn) J. Biol. Chem., August 18, 2006; 281(33): 23514 - 23524. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
